First migraine pill recommended for NHS use in England

Getty/fizkes

By Sarah Lowden

The first oral treatment option for preventing chronic and episodic migraines has been recommended for use on the NHS in England, in final draft guidance from the National Institute for Health and Care Excellence.

Atogepant – a once-a-day tablet sold under the brand name Aquipta and made by AbbVie – has been recommended for adult patients who have had at least 4 migraine days per month and where at least three previous preventive treatments have failed.